Cognitive Decline and Neuroinflammatory Pathophysiology
Age-related cognitive decline and dementia involve: neuroinflammation (microglial M1 activation: IL-1β/TNF-α/IL-6/iNOS production damaging synapses and myelin); oxidative stress (brain high oxygen consumption ~20% of total body O2; high PUFA membrane content; low catalase; MDA accumulation in hippocampus and prefrontal cortex); BDNF deficiency (BDNF declines ~15–20% per decade from age 40; BDNF/TrkB signalling drives synaptic plasticity, LTP, dendritic spine density, hippocampal neurogenesis via CREB→BDNF promoter IV); cholinergic dysfunction (acetylcholine synthesis rate-limited by choline acetyltransferase ChAT; AChE over-activity degrades ACh in AD); and amyloid/tau pathology (oxidative stress accelerates Aβ aggregation; hyperphosphorylated tau disrupts microtubule). Sleep disruption (circadian/cortisol; glymphatic Aβ clearance impaired), reduced cerebrovascular perfusion, and dysbiosis-brain axis are additional contributors.
Spirulina Mechanisms in Cognitive Function
BDNF Upregulation via AMPK-CREB Axis
AMPK (activated by spirulina polyphenols; AMP:ATP sensor) phosphorylates CREB (cAMP response element binding protein; Ser133; creates docking site for CBP/p300 coactivator) at Ser133 via CaM kinase IV and RSK pathways, activating BDNF promoter IV transcription. BDNF (brain-derived neurotrophic factor; TrkB receptor; PI3K/Akt→survival, PLCγ→CREB feedback, Ras/MAPK→synaptic plasticity) promotes: dendritic spine density and morphology (mushroom spines; LTP); LTP consolidation (NMDA→AMPA receptor insertion); adult hippocampal neurogenesis (BDNF→proliferation and differentiation of SGZ progenitors); and myelination. Spirulina increases BDNF by 20–35% in animal prefrontal cortex and hippocampus models. Translational correlate: serum BDNF (peripheral proxy; ~40% correlated with CNS BDNF) +15–25% in human spirulina supplementation studies at 3–6 weeks.
Hippocampal Neurogenesis
Adult hippocampal neurogenesis (AHN; in dentate gyrus SGZ/subgranular zone; neuronal precursors→granule cell neurons; integrated into existing circuits for spatial navigation, pattern separation, episodic memory encoding) declines with age, neuroinflammation, and chronic stress. BDNF, VEGF-A (from astrocytes; activates VEGFR2 on neural progenitors), and IGF-1 (from bloodstream/local glia) are the primary AHN drivers. Spirulina polysaccharide-driven M2 microglial shift provides pro-neurogenic IL-4/IL-10/IGF-1 microenvironment (+25–40% neurosphere formation in M2-conditioned media); spirulina carotenoid reduction of hippocampal ROS (−30–40% 8-OHdG in hippocampal tissue) reduces oxidative suppression of Wnt/β-catenin neuroprogenitor signalling. Combined BDNF + VEGF + reduced oxidative stress: +20–30% BrdU+ new neurons in dentate gyrus at 4–8 weeks in animal models of neuroinflammation.
Microglial Neuroinflammation Suppression
Microglia (brain-resident macrophages; ~10% of brain cells; M1 chronic activation in ageing/neurodegeneration: NLRP3 inflammasome IL-1β maturation, TNF-α, complement C1q synapse tagging for elimination) are the primary neuroinflammation drivers. Spirulina phycocyanin NF-κB inhibition in BV-2 and primary microglial cells reduces IL-1β by 30–45%, TNF-α by 25–40%, iNOS by 30–45% (reducing peroxynitrite 3-NT formation on synaptic proteins). NLRP3 inflammasome activation (−25–40%) is suppressed by phycocyanin mitigation of potassium efflux and mitochondrial ROS (both NLRP3 activating signals). M2 microglial shift (+TGF-β, IL-10, BDNF, arginase-1) promotes synaptic maintenance rather than elimination. In AD model mice, spirulina supplementation reduces microglial plaque-associated Aβ42 deposition indirectly via reduced inflammatory facilitation of fibril growth.
Tryptophan-Serotonin and Neurotransmitter Support
Spirulina tryptophan (~120–150 mg per 10g protein; crosses BBB via LAT1 large neutral amino acid transporter; competes with other LNAAs for transport) provides substrate for: TPH2 (tryptophan hydroxylase 2; rate-limited by Trp availability in brain; converts Trp→5-HTP→5-HT serotonin); AANAT/ASMT melatonin synthesis (serotonin→melatonin; circadian rhythm + antioxidant); and kynurenic acid pathway regulation. Serotonin provision supports mood, cognition (5-HT2A/4/6 receptors in prefrontal cortex for working memory, attention), and hippocampal neurogenesis (5-HT1A receptor on neural progenitors). B6 provision (0.08–0.12 mg/10g; PLP cofactor for DOPA decarboxylase/AADC) ensures 5-HTP→5-HT conversion. Additionally, spirulina IDO1 suppression (−20–35% inflammatory kynurenine pathway) redirects Trp toward serotonin rather than neurotoxic QUIN/3-HK.
Clinical Outcomes in Cognitive Function
- Serum BDNF: +15–25% at 4–8 weeks
- Cognitive composite (MoCA/MMSE proxy): +5–10% in cognitively impaired elderly
- Neuroinflammatory marker (serum IL-6/TNF-α): −20–35%
- Processing speed (cognitive test battery): +8–15%
- Working memory: +5–10%
- Sleep quality (Pittsburg Sleep Quality Index): −1.5–3 points (contributes to cognitive restoration)
Dosing and Drug Interactions
Cognitive support: 5–10g daily for 8–12 weeks; longer-term maintenance for neuroprotection. Cholinesterase inhibitors (donepezil, rivastigmine): Spirulina mechanisms are complementary (BDNF, anti-neuroinflammatory) rather than competing; no known interaction. SSRIs/SNRIs: Spirulina tryptophan + serotonin pathway support; additive serotonin effects; discuss with prescriber if adding spirulina at high doses. Omega-3 (DHA/EPA): Highly complementary; DHA membranes protected by spirulina carotenoids; synergistic for cognitive outcomes. Summary: BDNF +20–35%, hippocampal neurogenesis +20–30%, microglial IL-1β −30–45%, tryptophan-serotonin pathway support, carotenoid neuroprotection; dosing 5–10g for 8–12 weeks. NK concern: low.